Cancers & treatments·Regimen libraryInduction

VRd

Checked 2026-09-09

Newly diagnosed myeloma (with daratumumab as D-VRd in transplant-eligible patients)

One cycle

every 21 days × 8 · about 24 weeks in total

21-day cycle × 8 (SWOG S0777); 4-6 before transplant (about 24 weeks)SubcutaneousOral Daily oral course

Components

Drug	Dose	Route	Days
Bortezomib Proteasome inhibitor	1.3 mg/m²	SC	D1, 4, 8, 11
Lenalidomide Immunomodulatory drug (cereblon E3 ligase modulator)	25 mg once daily	Oral	D1-14
Dexamethasone	20 mg	Oral	D1, 2, 4, 5, 8, 9, 11, 12

Cycles

8 (SWOG S0777); 4-6 before transplant

21-day cycle

Emetogenicity

Minimal (<10%)

G-CSF

Not routine

Notes

Weekly bortezomib (VRd-lite, 35-day cycles) is standard for frail patients.
Thromboprophylaxis with lenalidomide-dexamethasone; herpes zoster prophylaxis with bortezomib.

Used in

Multiple myeloma

Trials

PERSEUS IMROZ

Products

BortezomibLenalidomide

Source

SWOG S0777, Lancet 2017

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.